These findings support the rationale for clinical testing of peripheral CB1R blockers that are currently being developed in preclinical settings for the treatment of CYP-induced cystitis in oncologic patients as well as other systemic conditions associated with LUTSs. The gene discussed is CNR1; the disease is cystitis.